Trial · NCT07533487
Adding Neuromodulation Technique to Cognitive Behavior Therapy on Fibromyalgia in Postmenopausal Women
NCT07533487, Not applicable, Completed, Cairo University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adding Neuromodulation Technique to Cognitive Behavior Therapy on Fibromyalgia in Postmenopausal Women. Trials, record NCT07533487. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07533487
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adding Neuromodulation Technique to Cognitive Behavior Therapy on Fibromyalgia in Postmenopausal Women
- NCT number
- NCT07533487
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 60 participants, actual
- Lead sponsor
- Cairo University
- Conditions
- Fibromyalgia
- Interventions
- TENS, Cognitive behavior therapy, medical treatment
- First posted
- 2026-04-16
- Last updated
- 2026-06-10
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of the pain distribution | 12 weeks | The Widespread Pain Index (WPI) is a self-report index measure that was used to assess bodily distribution of pain and to specifically quantify the degree of widespread body pain and assess for pain features (e.g., cognitive, emotional, and physical symptoms). The WPI assesses the presence of pain in 19 designated body locations over the past 7 days, such as the neck, right upper arm, left lower leg. Each location is equal to a score of 1. |
| Secondary | Symptom Severity Scale (SSI) | Baseline and after 12 weeks | A total SSS score ranged from 0 to 12, with each score ranging from zero to three. Zero indicated no problem, one indicated slight or mild problems, two indicated moderate problems, and three indicated severe problems . |
| Secondary | Assessment of pain threshold | Baseline and after 12 weeks | A pressure algometer was used to deliver pressure pain on a skin area of 1 cm2 between the thumb and index finger |
| Secondary | Assessment of heart rate variability (HRV) | Baseline and after 12 weeks | Electrocardiogram signal (ECG) (Philips Medical Systems, 3000 Minuteman Rd, Andover MA01810, USA). All signals were blindly analyzed. The acquisition of electrocardiogram signal (ECG) was performed immediately before and after the interventions for 10 minutes |
| Secondary | Assessment of fibromyalgia symptoms | Baseline and after 12 weeks | The questionnaire consists of 20 item that measure physical function like (feel good (1 item), missed work (1 item), do job (1 item), pain (1 item), fatigue (1 item), rested (1 item), stiffness (1 item), and cognitive function like (anxiety (1 item), and depression (1 item). Each patient in all groups was carefully instructed about the questionnaire. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07533487
GET https://conductscience.org/api/trials/v1/NCT07533487/registered